uniQure

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

2 Stories Indexed

Last Updated: Just Now

Verified Entity Intelligence

Global Markets & Equities Just now (03:25 PM IST)

uniQure Shares Plunge as Huntington’s Gene Therapy Data Fall Short of Investor Hopes

uniQure shares slumped after additional data from its Huntington’s disease gene therapy program failed to meet market expectations, despite indications the treatment may continue to slow disease progression over time. The reaction underscores how high the bar remains for experimental neuroscience therapies, where investors are demanding clearer efficacy, durability and safety signals before assigning premium valuations.

By RDU Global Wire5 min read

Global Markets & EquitiesJust now (03:39 AM IST)

uniQure Shares Tumble as Huntington’s Gene Therapy Data Undercut Investor Expectations

uniQure’s stock fell sharply after updated data from its Huntington’s disease gene therapy program failed to meet investor hopes, despite evidence the treatment may still slow disease progression over time. The reaction rippled beyond the company, with ClearPoint Neuro also sliding as markets reassessed the commercial and clinical outlook for the broader program.

5 min readRead →

🏢 About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside uniQure:

Washington, D.C.(2)ClearPoint Neuro(1)